Skip to content

Ian M. Waxman

Bristol-Myers Squibb (United States)

2 papers in the Anchorcite directory, published between 2014 and 2015, cited 11,561 times in total.

Research topics

Frequent co-authors

Papers

  1. Nivolumab versus Everolimus in Advanced Renal-Cell CarcinomaNew England Journal of Medicine · 2015 · 5,913 citations

    BACKGROUND: Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated with encouraging overall survival in uncontrolled studies involving previously treated patients with advanced renal-cell carcinoma. This randomized, open-label, phase 3 study compared nivolumab with everolimus in patients with renal-cell…

  2. Nivolumab in Previously Untreated Melanoma without BRAF MutationNew England Journal of Medicine · 2014 · 5,648 citations

    BACKGROUND: Nivolumab was associated with higher rates of objective response than chemotherapy in a phase 3 study involving patients with ipilimumab-refractory metastatic melanoma. The use of nivolumab in previously untreated patients with advanced melanoma has not been tested in a…

Metadata from OpenAlex (CC0).